When Pandemic Ends, EUA Recipients May Face Litigation And Enforcement Actions

Manufacturers face risk of whistle-blower suits and government enforcement actions when emergency use authorizations expire and pandemic recedes, attorneys say, but interaction with FDA and documentation may mitigate risk.